Cancer Research UK Manchester Centre

What Cancer Research UK Manchester Centre does

The Cancer Research UK Manchester Centre is a translational cancer research organisation operating as a partnership between Cancer Research UK, The University of Manchester, and The Christie NHS Foundation Trust, founded in 2020. It delivers research across six cross-cutting themes: Cancer Early Detection, Cancer Biomarkers, Digital Cancer, Experimental Cancer Medicine, Integrative Pathology, and Radiotherapy BioAdaption. The centre co-locates 300 scientists with 400 clinicians and operational staff in the newly completed Christie Paterson Building (over 25,000 square metres, ten storeys, opened June 2023 after a 2017 fire), which the input data describes as Europe's largest concentration of cancer researchers. Core programmes include the £50m International Alliance for Cancer Early Detection (ACED), RadNet Manchester (£5.9m radiotherapy research funded 2024), the National Biomarker Centre (opened June 2024 with £2.5m annual CRUK investment), the MB-PhD training programme, and the BCAN-RAY breast cancer risk study.

The centre's technical capabilities span MRI-Linac guided radiotherapy, SWATH-MS mass spectrometry with machine-learning-driven biomarker discovery (achieving over 95% accuracy in a womb cancer diagnostic test), AI-powered virtual clinical trials using digital twin simulation, and liquid biopsy biomarker detection. It does not sell products commercially; instead, it operates a charitable funding model receiving grants from Cancer Research UK (including a £58.7m Clinical Academic Training Programme allocation across nine centres with £8.5m to Manchester), philanthropic donations (e.g., £1m+ from the Sarah Harding Breast Cancer Appeal), and partnership funding. Outputs flow to patients through The Christie NHS Foundation Trust's clinical pipeline, to the academic community through publications and postgraduate training, and to industry through the MCRC Springboard Awards commercialisation pathway run with Cancer Research Horizons and the University of Manchester Innovation Factory. Customer segments include cancer patients participating in clinical trials, postgraduate medical and research students, academic and clinical researchers, and the general public engaged through outreach programmes.

Recent strategic activity has been substantial: in the 2024-2025 period the centre opened the National Biomarker Centre, secured £5.9m RadNet funding, received its £8.5m share of the Clinical Academic Training Programme, and expanded ACED with Dana-Farber Cancer Institute and the German Cancer Research Centre. The centre is led by Director Professor Rob Bristow, with Professor Caroline Dive directing the National Biomarker Centre and Professor Kaye Williams serving as Deputy Director of CRUK RadNet Manchester. The combination of physical infrastructure investment, sustained CRUK commitment, and expanding international alliance membership indicates a growth-phase research organisation despite its non-commercial structure.

Name

Cancer Research UK Manchester Centre

Legal name

The University of Manchester

Website

https://crukcentre.manchester.ac.uk

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

The Cancer Research UK Manchester Centre is a translational cancer research partnership between Cancer Research UK, The University of Manchester, and The Christie NHS Foundation Trust, delivering discovery-to-clinic research across six themes for cancer patients, clinicians, and researchers.

Ownership category

akta.pro rank

Product category

Translational Cancer Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD)

Keywords

• Translational cancer research
• Clinical academic training
• Cancer biomarker discovery
• Radiotherapy research
• Cancer early detection

Headquarters

HQ city

Manchester

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Charitable Funding and Grants: Primary funding from Cancer Research UK through the Clinical Academic Training Programme (£58.7m across nine centres) and other research grants
2. Radiotherapy Research Funding: CRUK RadNet investment of £5.9 million for radiotherapy research programme over five years
3. National Biomarker Centre Funding: £2.5m annual investment from Cancer Research UK as part of £26m total Manchester investment
4. Philanthropic Donations: Funding from The Christie Charity, Sarah Harding Breast Cancer Appeal (£1 million raised), and other charitable donations

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Cancer Research UK Manchester Centre conducts translational cancer research across six themes (Cancer Early Detection, Cancer Biomarkers, Digital Cancer, Experimental Cancer Medicine, Integrative Pathology, and Radiotherapy BioAdaption). It delivers clinical trials, biomarker discovery, radiotherapy research, and clinical academic training programmes (MB-PhD, Clinical Research Training Fellowships) for cancer researchers and clinicians. Outputs are translated into patient care through The Christie NHS Foundation Trust partnership.

Product overview

Cancer Research UK Manchester Centre is a translational research centre delivering world-leading research across six cross-cutting themes: Cancer Early Detection, Cancer Biomarkers, Digital Cancer, Experimental Cancer Medicine, Integrative Pathology, and Radiotherapy BioAdaption. The centre operates through a portfolio of dedicated research programmes including the International Alliance for Cancer Early Detection (ACED), RadNet Manchester radiotherapy research, and the National Biomarker Centre. Training and innovation support is provided through the MB-PhD Programme and MCRC Springboard Awards. Key research capabilities include virtual clinical trials using AI simulations, advanced biomarker discovery using mass spectrometry and machine learning, and novel diagnostic test development.

Differentiator

Problem solved

Functional benefit

Brands

• RadNet Manchester: Radiation Research Unit in collaboration with The Christie NHS Foundation Trust developing new clinical treatments in radiation oncology
• ACED Manchester
• National Biomarker Centre

Products and services

• MB-PhD Programme
• Clinical Research Training Fellowships and Non-Clinical PhD Studentships
• National Biomarker Centre Services
• RadNet Manchester Radiotherapy Research Programme
• Womb Cancer Diagnostic Test
• Virtual Clinical Trials
• BCAN-RAY Study
• MCRC Springboard Awards

Quantifiable outcome

• Over 95% accuracy in identifying womb cancer in post-menopausal women
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

13 partnerships are on record, tiered flagship, core and minor.

• International Alliance for Cancer Early Detection (ACED) - Dana-Farber Cancer InstituteflagshipStrategic or Co-development Partner · 18 February 2025£50m international partnership expanding to include Dana-Farber Cancer Institute (USA) and German Cancer Research Centre (Europe). The alliance brings together leading institutions to accelerate cancer early detection research.
• International Alliance for Cancer Early Detection (ACED) - German Cancer Research Centre (DKFZ)flagshipStrategic or Co-development Partner · 18 February 2025German Cancer Research Centre joins the £50m ACED partnership alongside Dana-Farber, bringing European expertise to the international alliance for cancer early detection.
• The Christie NHS Foundation TrustcoreStrategic or Co-development Partner · 9 June 2023The Christie has been at the forefront of cancer research for over 120 years. Standard treatments first trialled at The Christie have improved outcomes for millions of patients globally. The partnership forms the largest single-site cancer centre in Europe, delivering clinical trials from prevention through to living with and beyond cancer.
• The University of Manchester - Division of Cancer SciencescoreStrategic or Co-development PartnerThe University of Manchester provides academic leadership and research expertise, with staff from the Division of Cancer Sciences working side-by-side with CRUK Manchester Institute and The Christie colleagues to generate new ideas, make discoveries, and devise next-generation therapies.
• International Alliance for Cancer Early Detection (ACED) - University of CambridgeflagshipStrategic or Co-development PartnerFounding partner of the £50m ACED alliance focused on developing tools to detect cancer earlier when treatment is more likely to be successful.
• International Alliance for Cancer Early Detection (ACED) - University College LondonflagshipStrategic or Co-development PartnerFounding partner of the ACED alliance bringing together UK expertise in cancer early detection research.
• International Alliance for Cancer Early Detection (ACED) - Knight Cancer Institute at OHSUflagshipStrategic or Co-development PartnerUS partner in the ACED alliance contributing international perspective and research expertise to early cancer detection.
• International Alliance for Cancer Early Detection (ACED) - Canary Center at Stanford UniversityflagshipStrategic or Co-development PartnerUS founding partner contributing pioneering early detection research expertise to the ACED alliance.
• CRUK RadNet NetworkflagshipStrategic or Co-development PartnerManchester is one of seven centres of excellence in the UK-wide RadNet network accelerating advances in radiotherapy research. The centre received £5.9m second wave investment for pioneering radiotherapy research.
• Manchester University NHS Foundation Trust (MFT)coreStrategic or Co-development PartnerBCAN-RAY study taking place at The Nightingale Centre at Wythenshawe Hospital, part of MFT, recruiting 1,000 women aged 30-39 for breast cancer risk research.
• University of SurreyminorStrategic or Co-development PartnerCollaborator on womb cancer diagnostic test research led by University of Manchester, specifically Professor Anthony Whetton's involvement in protein biomarker identification.
• University of Manchester Innovation FactorycoreStrategic or Co-development PartnerCommercialisation arm of the University driving technology transfer and supporting MCRC Springboard Award winners in translating research from bench to bedside.
• Cancer Research HorizonscoreStrategic or Co-development PartnerCancer Research UK's innovation arm supporting Springboard Awards for early-stage innovations and providing commercialisation expertise alongside Innovation Factory.

Scale indicators13 records

Recent moves11 records

Expansion highlights6 records

Others

• European Organisation for Research and Treatment of Cancer (EORTC): Pan-European intergovernmental cancer clinical research organisation coordinating multinational trials. Comparable in translational cancer research focus though organised as a network rather than a single site.
• Wellcome Sanger Institute: UK genomics research institute whose large-scale sequencing and cell-line authentication capabilities underpin cancer genomics research. Comparable in scale and academic standing though not a dedicated cancer centre.
• Francis Crick Institute: Major UK biomedical research institute with cancer-relevant basic science but broader biology scope. Comparable in size and UK funding model, but not cancer-focused.

Broad incumbents

• National Cancer Institute (NCI): US federal agency funding and coordinating cancer research nationally, including designated comprehensive cancer centres. Comparable in translational mission but operates at nation-scale with much larger budget.

Direct peers

• Memorial Sloan Kettering Cancer Center: Comprehensive US cancer centre combining laboratory research with clinical care at scale. Closest North American analogue in scope, combining biomarker discovery, radiotherapy innovation, and clinical translation.
• MD Anderson Cancer Center: World's largest comprehensive cancer centre with deep translational research, biomarker, and radiotherapy programmes. Comparable in integrated bench-to-bedside mission though operating at considerably larger scale.
• The Institute of Cancer Research: UK-based cancer research institute with translational research programmes, hospital partnership (Royal Marsden), and CRUK funding. Highly comparable in mission, scale and funding model to CRUK Manchester Centre.
• German Cancer Research Centre (DKFZ): Germany's national cancer research centre covering translational research, biomarkers, radiotherapy, and early detection. Directly comparable in scope and is now an ACED partner alongside CRUK Manchester Centre.
• Dana-Farber Cancer Institute: US Harvard-affiliated cancer centre with translational research, precision medicine, and clinical trials programmes. Now a co-partner in ACED with directly overlapping research priorities.

Regional players

• Ontario Institute for Cancer Research (OICR): Canadian translational cancer research institute focused on genomics, biomarkers, and clinical translation. Comparable in mission and translational orientation though serving a different national jurisdiction.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cancer-research-uk-manchester-centre

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer Research UK Manchester Centre